Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.
Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.